Efstathios S. Gonos

Dr. Efstathios S. Gonos


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SKSuzanne Kapeta
Suzanne Kapeta
Niki ChondrogianniNiki Chondrogianni
Niki Chondrogianni
Efstathios S. GonosEfstathios S. Gonos
Efstathios S. Gonos
Replicative senescence in human fibroblasts is accompanied with alterations of various biological processes, including the impaired function of the proteasome. The proteasome is responsible for the removal of both normal and damaged proteins. Due to its latter function, proteasome is also considered a representative secondary antioxidant cellular mechanism. Nrf2 is a basic transcription factor responsible for the regulation of the cellular antioxidant response that has also been shown to regulate several proteasome subunits in mice. We have established in this study the proteasome-related function of Nrf2 in human fibroblasts undergoing replicative senescence. We demonstrate that Nrf2 has a declined function in senescence, whereas its silencing leads to premature senescence. However, upon its activation by a novel Nrf2 inducer, elevated levels of proteasome activity and content are recorded only in cell lines possessing a functional Nrf2. Moreover, treatment by the Nrf2 inducer results in the enhanced survival of cells following oxidative stress, whereas continuous treatment leads to lifespan extension of human fibroblasts. Importantly the Nrf2-proteasome axis is functional in terminally senescent cultures as these cells retain their responsiveness to the Nrf2 stimuli. In conclusion, these findings open up new directions for future manipulation of the senescence phenotype.

13 November 2014 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
Niki ChondrogianniNiki Chondrogianni
Niki Chondrogianni
KGKonstantina Georgila
Konstantina Georgila
NKNikos Kourtis
Nikos Kourtis
Nektarios TavernarakisNektarios Tavernarakis
Nektarios Tavernarakis
Efstathios S. GonosEfstathios S. Gonos
Efstathios S. Gonos
Protein homeostasis (proteostasis) is one of the nodal points that need to be preserved to retain physiologic cellular/organismal balance. The ubiquitin‐proteasome system (UPS) is responsible for the removal of both normal and damaged proteins, with the proteasome being the downstream effector. The proteasome is the major cellular protease with progressive impairment of function during aging and senescence. Despite the documented age‐retarding properties of proteasome activation in various cellular models, simultaneous enhancement of the 20S core proteasome content, assembly, and function have never been reported in any multicellular organism. Consequently, the possible effects of the core proteasome modulation on organismal life span are elusive. In this study, we have achieved activation of the 20S proteasome at organismal level. We demonstrate enhancement of proteasome levels, assembly, and activity in the nematode Caenorhabditis elegans , resulting in life span extension and increased resistance to stress. We also provide evidence that the observed life span extension is dependent on the transcriptional activity of Dauer formation abnormal/Forkhead box class O (DAF‐16/FOXO), skinhead‐1 (SKN‐1), and heat shock factor‐1 (HSF‐1) factors through regulation of downstream longevity genes. We further show that the reported beneficial effects are not ubiquitous but they are dependent on the genetic context Finally, we provide evidence that proteasome core activation might be a potential strategy to minimize protein homeostasis deficiencies underlying aggregation‐related diseases, such as Alzheimer's disease (AD) or Huntington's disease (HD). In summary, this is the first report demonstrating that 20S core proteasome up‐regulation in terms of both content and activity is feasible in a multicellular eukaryotic organism and that in turn this modulation promotes extension of organismal health span and life span.—Chondrogianni, N., Georgila, K., Kourtis, N., Tavernarakis, N., Gonos, E. S. 20S proteasome activation promotes life span extension and resistance to proteotoxicity in Caenorhabditis elegans. FASEB J . 29, 611‐622 (2015). www.fasebj.org

1 February 2014 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
Niki ChondrogianniNiki Chondrogianni
Niki Chondrogianni
IPIsabelle Petropoulos
Isabelle Petropoulos
SGStefanie Grimm
Stefanie Grimm
KGKonstantina Georgila
Konstantina Georgila
BCBetul Catalgol
Betul Catalgol
Efstathios S. GonosEfstathios S. Gonos
Efstathios S. Gonos

1 March 2004 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ITIoannis P. Trougakos
Ioannis P. Trougakos
ASAlan So
Alan So
BJBurkhard Jansen
Burkhard Jansen
MGMartin E. Gleave
Martin E. Gleave
Efstathios S. GonosEfstathios S. Gonos
Efstathios S. Gonos
Clusterin/Apolipoprotein J (CLU) is a heterodimeric ubiquitously expressed secreted glycoprotein that is implicated in several physiological processes and is differentially expressed in many severe physiological disturbances, including tumor formation and in vivo cancer progression. Despite extensive efforts, clarification of CLU’s biological role has been exceptionally difficult and its precise function remains elusive. Short RNA duplexes, referred to as small interfering RNAs (siRNAs), provide a new approach for the elucidation of gene function in human cells. Here, we describe siRNA-mediated CLU gene silencing in osteosarcoma and prostate human cancer cells and illustrate that CLU mRNA is amenable to siRNA-mediated degradation. Our data demonstrate that CLU knockdown in human cancer cells induces significant reduction of cellular growth and higher rates of spontaneous endogenous apoptosis. Moreover, CLU knockdown cancer cells were significantly sensitized to both genotoxic and oxidative stress induced by chemotherapeutic drugs and H2O2, respectively. These effects were more pronounced in cell lines that express high endogenous steady-state levels of the CLU protein and occur through hyperactivation of the cellular apoptotic machinery. Overall, our results reveal that, in the distinct cellular contexts of the osteosarcoma and prostate cancer cells assayed, CLU is a central molecule in cell homeostasis that exerts a cytoprotective function. The described CLU-specific siRNA oligonucleotides that can potently silence CLU gene expression may thus prove valuable agents during antitumor therapy or at other pathological conditions where CLU has been implicated.

18 July 2020 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
ACAlan A. Cohen
Alan A. Cohen
BKBrian K. Kennedy
Brian K. Kennedy
UAUlrich Anglas
Ulrich Anglas
ABAnne M. Bronikowski
Anne M. Bronikowski
JDJoris Deelen
Joris Deelen
Tamas FulopTamas Fulop
Tamas Fulop

31 December 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ITIoannis P. Trougakos
Ioannis P. Trougakos
MLMagda Lourda
Magda Lourda
MAMarianna Antonelou
Marianna Antonelou
Dimitris KletsasDimitris Kletsas
Dimitris Kletsas
VGVassilis G. Gorgoulis
Vassilis G. Gorgoulis
Efstathios S. GonosEfstathios S. Gonos
Efstathios S. Gonos
Purpose: Secretory clusterin (sCLU)/apolipoprotein J is an extracellular chaperone that has been functionally implicated in DNA repair, cell cycle regulation, apoptotic cell death, and tumorigenesis. It exerts a prosurvival function against most therapeutic treatments for cancer and is currently an antisense target in clinical trials for tumor therapy. However, the molecular mechanisms underlying its function remained largely unknown. Experimental Design: The molecular effects of small interfering RNA-mediated sCLU depletion in nonstressed human cancer cells were examined by focusing entirely on the endogenously expressed sCLU protein molecules and combining molecular, biochemical, and microscopic approaches. Results: We report here that sCLU depletion in nonstressed human cancer cells signals stress that induces p53-dependent growth retardation and high rates of endogenous apoptosis. We discovered that increased apoptosis in sCLU-depleted cells correlates to altered ratios of proapoptotic to antiapoptotic Bcl-2 protein family members, is amplified by p53, and is executed by mitochondrial dysfunction. sCLU depletion-related stress signals originate from several sites, because sCLU is an integral component of not only the secretory pathway but also the nucleocytosolic continuum and mitochondria. In the cytoplasm, sCLU depletion disrupts the Ku70-Bax complex and triggers Bax activation and relocation to mitochondria. We show that sCLU binds and thereby stabilizes the Ku70-Bax protein complex serving as a cytosol retention factor for Bax. Conclusions: We suggest that elevated sCLU levels may enhance tumorigenesis by interfering with Bax proapoptotic activities and contribute to one of the major characteristics of cancer cells, that is, resistance to apoptosis.